Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 18/20 | 0.43 |
| ▸ | BCHE | P06276 | 4/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4127558 | 1.00 | ACHE (0.43) | ACHEBCHETRPM8SLC6A2SLC6A4 | |
| SCHEMBL4127515 | 0.95 | ACHE (0.45) | ACHEBCHETRPM8 | |
| Fumaric Acid SCHEMBL4134234 | 0.92 | ACHE (0.40) | ACHEBCHE | |
| Fumaric Acid SCHEMBL4134229 | 0.92 | ACHE (0.40) | ACHEBCHE | |
| Fumaric Acid SCHEMBL4125665 | 0.91 | ACHE (0.46) | ACHEBCHE | |
| Fumaric Acid SCHEMBL4125669 | 0.91 | ACHE (0.46) | ACHEBCHE | |
| Fumaric Acid SCHEMBL4127556 | 0.89 | ACHE (0.44) | ACHEBCHE | |
| Fumaric Acid SCHEMBL4121277 | 0.88 | ACHE (0.42) | ACHEBCHE | |
| Fumaric Acid SCHEMBL4120407 | 0.88 | ACHE (0.42) | ACHEBCHE | |
| Fumaric Acid SCHEMBL4120404 | 0.88 | ACHE (0.42) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | SLC6A2 1758/4885SLC6A4 1398/4885ACHE 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.